Skip to main content

Table 3 Absolute and relative differences in mean dose and BED between sequential boost and the simultaneous integrated boost using the same prescribed biologically effective dose with α/β = 10 Gy (BED10) and 3 Gy (BED3) for all structures of the ten studied patients (mean ± SD)

From: Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH)

  Dose (Gy) (SIB10/SEQ–1) × 100 Dose (Gy) (SIB3/SEQ–1) × 100
Dose (%) BED10 (%) Dose (%) BED3 (%)
PTVboost −1.5 ± 0.7 −2 ± 1 0 ± 1 −3.0 ± 0.7 −5 ± 1 0 ± 2
PTVbreast −1.3 ± 0.8 −2 ± 1 −3 ± 1 a −0.6 ± 0.9 −1 ± 2 −2 ± 2 a
ILung −0.7 ± 0.4 −8 ± 4 −10 ± 4 a −0.8 ± 0.5 −9 ± 4 −11 ± 4 a
CBreast −0.1 ± 0.3 −6 ± 16 −6 ± 17 −0.1 ± 0.3 −5 ± 15 −6 ± 16
CLung −0.1 ± 0.1 −7 ± 13 −8 ± 14 −0.1 ± 0.2 −6 ± 17 −7 ± 18
Heartleft b −0.3 ± 0.5 −10 ± 16 −12 ± 16 −0.2 ± 0.1 −6 ± 4 −8 ± 4 a
Heartright c −0.3 ± 0.4 −12 ± 17 −14 ± 19 −0.2 ± 0.6 −8 ± 24 −10 ± 25
  1. aIndicates a significant difference (p <0.05) between the SEQ and SIB plans in term of BED
  2. bGroup of 6 patients with left-sided breast tumor
  3. cGroup of 4 patients with right-sided breast tumor